Bangalore, September 24, 2020: Dr. Manjiri Bakre, Founder & CEO OncoStem Diagnostics, was awarded ‘Health Tech Innovator of the Year’ by ET Healthworld – Intelligent Health & Tech awards 2020.
ET Healthworld.com’s Intelligent Health & Tech Awards 2020 (IHTA) honours hard work, innovation and excellence of healthcare-focused AI & Tech enterprises and individuals across 30+ categories in a number of functional areas like telemedicine services, m-health applications and medical device innovation. It provides a platform to the game changers, innovators and achievers of AI & Tech companies, who have shown exemplary performance and have aided the growth of the healthcare industry, to claim their fame and inspire others to outshine them. Screening of applications was conducted by KPMG and some of the jury members were Dr. Atul Mohan Kochhar, CEO, NABH; Dr. Girdhar J. Gyani, (Jury Chair), Director General, Association of Healthcare Providers India; Rakesh Mishra, Director, CSIR-CCMB Ministry of Science & Technology, Government of India and others.
Commenting on the award, Dr. Manjiri Bakre said, “I am extremely happy to receive this award and to be recognized by a prestigious platform like ET Healthworld. At OncoStem,we have always believed that technology has the potential to redefine cancer care and treatment. Our AI based prognostic test has helped a number early stage breast cancer patients avoid over treatment of cancer. This recognition further strengthens our commitment towards customizing breast cancer treatment by allowing low-risk patients to avoid chemotherapy.”
OncoStem’s CanAssist Breast is a prognostic test for early-stage hormone receptor positive breast cancer patients. It makes customized treatment possible by analysing the patients tumor in depth and providing a patient specific report. CanAssist Breast categorizes patients based on the risk of cancer recurrence clearly as either ‘low or high’ with no grey area in between. This clear distinction of patients based on risk of cancer recurrence allows doctors to devise treatment plans that are in tune with the prognosis, maintaining a balance between the benefits and side effects. Patients who are at low risk of relapse can potentially avoid chemotherapy and its associated side-effects while patients who are at high risk of relapse would benefit from the addition of chemotherapy to their treatment regimen.